| |
Outcomes on CLART, N (%)
|
|---|
|
Any high-risk genotype (%)b
|
No high-risk genotypes (%)c
|
Only low-risk genotypes (%)b
|
Invalid (%)
|
Total (%)
|
|---|
|
Total
|
1,024 (23.2%)
|
3,375 (76.5%)
|
528 (12.0%)
|
11 (0.2%)
|
4,410 (100%)
|
|
Age (years)
| | | | | |
|
16-22
|
77 (57.0%)
|
58 (43.0%)
|
18 (13.3%)
|
0 (0.0%)
|
135 (100%)
|
|
23-29
|
485 (37.7%)
|
801 (62.2%)
|
175 (13.6%)
|
1 (0.1%)
|
1,287 (100%)
|
|
30-39
|
274 (21.1%)
|
1,021 (78.6%)
|
139 (10.7%)
|
4 (0.3%)
|
1,299 (100%)
|
|
40-49
|
116 (12.8%)
|
783 (86.6%)
|
104 (11.5%)
|
5 (0.6%)
|
904 (100%)
|
|
50-59
|
45 (9.7%)
|
419 (90.1%)
|
55 (11.8%)
|
1 (0.2%)
|
465 (100%)
|
|
60-65
|
19 (8.8%)
|
196 (91.2%)
|
22 (10.2%)
|
0 (0.0%)
|
215 (100%)
|
|
>65
|
8 (7.6%)
|
97 (92.4%)
|
15 (14.3%)
|
0 (0.0%)
|
105 (100%)
|
|
Cytology
| | | | | |
|
Normal
|
847 (20.4%)
|
3,290 (79.3%)
|
494 (11.9%)
|
11 (0.3%)
|
4,148 (100%)
|
|
ASCUS
|
49 (57.6%)
|
36 (42.4%)
|
9 (10.6%)
|
0 (0.0%)
|
85 (100%)
|
|
LSIL
|
64 (73.6%)
|
23 (26.4%)
|
20 (23.0%)
|
0 (0.0%)
|
87 (100%)
|
|
≥HSIL
|
64 (92.8%)
|
5 (7.2%)
|
2 (2.9%)
|
0 (0.0%)
|
69 (100%)
|
|
≥ASCUS
|
177 (73.4%)
|
64 (26.6%)
|
31 (12.9%)
|
0 (0.0%)
|
241 (100%)
|
|
Inadequate
|
0 (0.0%)
|
21 (100%)
|
3 (14.3%)
|
0 (0.0%)
|
21 (100%)
|
|
HC2
d
| | | | | |
|
Positive
|
693 (84.3%)
|
128 (15.6%)
|
84 (10.2%)
|
1 (0.1%)
|
822 (100%)
|
|
Negative
|
330 (9.2%)
|
3,245 (90.5%)
|
444 (12.4%)
|
10 (0.3%)
|
3,585 (100%)
|
-
Abbreviations:
ASCUS atypical squamous cells of undetermined significance, HC2 Hybrid Capture 2 assay, HPV Human Papillomavirus, ≥HSIL high-grade intraepithelial lesions or worse, LSIL low-grade squamous intraepithelial lesions.
-
aPredominantly screening samples, including a small proportion of samples taken for indication.
-
bAccording to classification reported by IARC [2].
-
cConsidered negative on the CLART assay.
-
dThree samples were not tested with HC2.
